{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:10:15Z","timestamp":1793394615869,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82004238"],"award-info":[{"award-number":["82004238"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474449"],"award-info":[{"award-number":["82474449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004863","name":"Zhejiang Chinese Medical University","doi-asserted-by":"publisher","award":["2023FSYYZZ07"],"award-info":[{"award-number":["2023FSYYZZ07"]}],"id":[{"id":"10.13039\/501100004863","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.semarthrit.2025.152754","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:53:45Z","timestamp":1747220025000},"page":"152754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Infectious complications of Belimumab with standard care in systemic lupus erythematosus: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"73","author":[{"given":"Yu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5717-3602","authenticated-orcid":false,"given":"Weijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.semarthrit.2025.152754_bib0001","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"issue":"10188","key":"10.1016\/j.semarthrit.2025.152754_bib0002","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152754_bib0003","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/1744666X.2020.1763793","article-title":"Systemic lupus erythematosus and risk of infection","volume":"16","author":"Barber","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152754_bib0004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.berh.2005.05.006","article-title":"New treatments for SLE: cell-depleting and anti-cytokine therapies","volume":"19","author":"Anolik","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152754_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152754_bib0006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1756-185X.2009.01458.x","article-title":"The immunological basis of B-cell therapy in systemic lupus erythematosus","volume":"13","author":"Mok","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152754_bib0007","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"10.1016\/j.semarthrit.2025.152754_bib0008","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152754_bib0009","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/14740338.2019.1685978","article-title":"The safety of belimumab for the treatment of systemic lupus erythematosus","volume":"18","author":"Wise","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2025.152754_bib0010","article-title":"Dilemma of immunosuppression and infection risk in systemic lupus erythematosus","volume":"62","author":"He","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152754_bib0011","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/annrheumdis-2018-214802","article-title":"All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013)","volume":"78","author":"Tselios","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152754_bib0012","article-title":"Mudano AS. Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152754_bib0013","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152754_bib0014","doi-asserted-by":"crossref","unstructured":"Ginzler E., Guedes Barbosa L.S., D\u2019Cruz D., Furie R., Maksimowicz-McKinnon K., Oates J., et al. Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of Belimumab in patients of black African ancestry with systemic lupus erythematosus. Arthritis Rheumatol 74(1):112-123.","DOI":"10.1002\/art.41900"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152754_bib0015","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152754_bib0016","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152754_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous Belimumab in systemic Lupus Erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","author":"Stohl","year":"2017","journal-title":"Arthritis & rheumatology"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152754_bib0018","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152754_bib0019","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.clinthera.2016.02.022","article-title":"Efficacy and safety of Belimumab Plus standard therapy in patients with systemic Lupus erythematosus: a meta-analysis","volume":"38","author":"Wei","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2025.152754_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108811","article-title":"Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: a systematic review and meta-analysis of randomised controlled trials","volume":"109","author":"Xu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152754_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2207671","article-title":"Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2023","journal-title":"Ren Fail"},{"key":"10.1016\/j.semarthrit.2025.152754_bib0022","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152754_bib0023","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152754_bib0024","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152754_bib0025","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152754_bib0026","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"7304","key":"10.1016\/j.semarthrit.2025.152754_bib0027","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152754_bib0028","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2506","article-title":"Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus","volume":"10","author":"Furie","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152754_bib0029","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152754_bib0030","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2764","article-title":"Predictors of major infections in systemic lupus erythematosus","volume":"11","author":"Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152754_bib0031","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15188","article-title":"Non-adherence to hydroxychloroquine in systemic lupus erythematosus: the elephant in the clinic room","volume":"27","author":"Mok","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152754_bib0032","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.semarthrit.2025.152754_bib0033","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152754_bib0034","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.14997","article-title":"Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a phase 3, randomized, placebo-controlled trial in North East Asia","volume":"27","author":"Suh","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152754_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15385","article-title":"Recent advances in cellular immunotherapy for immune-mediated rheumatic diseases","volume":"28","author":"Wan","year":"2025","journal-title":"Int J Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T03:57:57Z","timestamp":1762228677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"alternative-id":["S0049017225001258"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152754","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious complications of Belimumab with standard care in systemic lupus erythematosus: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152754"}}